The recent surge in capital into boutique pharmaceutical companies, particularly those focusing on experimental therapies and challenging drug development programs, has fueled what some are calling "High Roller Pharma." While the potential for revolutionary treatments and impressive returns is undeniable, the connected risks are also considerable.